ANKRD18B Activators
ANKRD18B Activators encompass a variety of chemical compounds that enhance the functional activity of ANKRD18B through their influence on distinct signaling pathways. Forskolin, by escalating cAMP within the cell, indirectly heightens ANKRD18B's role by activating PKA, which phosphorylates proteins that can interact with ANKRD18B, thereby facilitating its involvement in signaling transduction. Concurrently, IBMX and 8-Br-cAMP support the ANKRD18B activity by preventing cAMP degradation and providing a cAMP analog, respectively, both leading to sustained PKA activation and subsequent phosphorylation of ANKRD18B-related proteins. The activation of PKC by PMA may also modify protein interactions with ANKRD18B, enhancingits activity. Similarly, EGCG, through kinase inhibition, may diminish the negative regulation on ANKRD18B-associated pathways, thus indirectly boosting ANKRD18B's role.
The activity of ANKRD18B is further affected by compounds targeting the PI3K/Akt pathway; LY294002 and Wortmannin, as PI3K inhibitors, potentially amplify ANKRD18B activity by modifying the phosphorylation landscape of the pathway. MEK1/2 inhibition by U0126, as well as p38 MAPK inhibition through SB203580, may realign signaling to favor ANKRD18B's involvement in cellular processes. Furthermore, the calcium ionophore A23187 elevates intracellular calcium, potentiating calcium-dependent signaling which is anticipated to enhance ANKRD18B's functional activity. Finally, Sildenafil and Zaprinast, by inhibiting PDE5 and elevating cGMP levels, can potentiate cGMP-dependent kinase pathways, potentially leading to an enhancement of ANKRD18B activity through altered phosphorylation dynamics associated with these signaling cascades. Collectively, these compounds act on varied molecular targets and signaling pathways that, while distinct, converge on the common outcome of augmenting ANKRD18B's functional participation in cellular signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin increases intracellular cAMP levels. Elevated cAMP activates PKA, leading to the phosphorylation of proteins that interact with ANKRD18B, thereby enhancing ANKRD18B's role in cellular processes such as signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP, leading to their accumulation. The resultant increase in PKA activity can enhance the phosphorylation status of substrates associated with ANKRD18B, thus enhancing its activity. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP is a cAMP analog that activates PKA. PKA activation can result in the phosphorylation of target proteins that modulate the functional activity of ANKRD18B, leading to its enhanced activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC). PKC phosphorylation can lead to changes in the protein-protein interactions involving ANKRD18B, thereby enhancing its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate (EGCG) is a polyphenol that can inhibit certain protein kinases. Inhibition of these kinases could reduce negative regulation of pathways involving ANKRD18B, leading to its enhanced activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can lead to alterations in downstream signaling pathways, which may enhance the activity of ANKRD18B due to changes in the phosphorylation patterns of associated proteins. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can affect downstream signaling pathways and potentially enhance the activity of ANKRD18B by altering the phosphorylation state of proteins in these pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38, it may shift cellular signaling to rely more on pathways involving ANKRD18B, thus indirectly enhancing its activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. Elevated calcium can activate calcium-dependent signaling pathways, which may enhance the functional activity of ANKRD18B. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, particularly PDE5, leading to increased cGMP levels. This may potentiate cGMP-dependent pathways and enhance the functional activity of ANKRD18B by influencing the phosphorylation of associated proteins. | ||||||